Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the FDA's recent approval of Bayer's finerenone in concomitant CKD and T1D.
Opinion|Podcasts|September 29, 2023
Untapped Potentials: Exploring Overlooked Therapies for Type 2 Diabetes
Listen
0:00 / 0:00
In this episode of MEDcast, the expert panelists examine some underutilized therapies in type 2 diabetes (T2D) and explore their potential as effective treatment choices for many patients.
Advertisement
0:50 Need for using older diabetes medications
3:30 Quick-release bromocriptine: benefits in T2D and cardiovascular risk
6:15 Efficacy of quick-release bromocriptine
8:10 Quick-release bromocriptine as monotherapy and as an add-on
9:00 Mechanism of quick-release bromocriptine
11:41 Titrating quick-release bromocriptine
15:50 Benefits of pioglitazone
22:30 Positioning older T2D therapies in the current treatment regimen
Advertisement
Related to this article
The approval, backed by FINE-ONE data showing a 28% UACR reduction at 6 months, is the first new CKD treatment for this group in 3 decades.
Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss Beta Bionics' new insulin patch pump, expected to be commercialized in Q1 2027.
Beta Bionics plans to launch Mint through the pharmacy channel in the first quarter of 2027.
Diana Isaacs, PharmD, and Natalie Bellini, DNP, unpack tirzepatide's new CV indication and the STAREE statin trial in older adults.
Advertisement
Advertisement
Trending on HCPLive
1
ASH Issues New Ferritin Thresholds for Iron Deficiency Diagnosis
2
Mavacamten’s Improvements in oHCM Symptoms Sustained in Long-Term Extension
3
Vicadrostat EASi-KIDNEY Trial Discontinued for Lack of Benefit in CKD
4
FDA Approves Finerenone (Kerendia) for CKD and Type 1 Diabetes
5